Neuroleptic malignant syndrome without neuroleptics

Singapore Medical Journal

Volumn 42, Issue 2, 2001, Pages 085-088

  Ong, K C ^a,b   Chew, E L ^a   Ong, Y Y ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Bromocriptine; Dopaminergic agents; Hyperthermia; Levodopa; Parkinsonism

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; CASE REPORT; DIAGNOSTIC ERROR; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTHERMIA; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; THOUGHT DISORDER;

ANTIPARKINSON AGENTS; BROMOCRIPTINE; CREATINE KINASE; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 6644227404     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Keyser DL, Rodnitzky RL. Neuroleplic malignant syndrome in Parkinson 's disease after withdrawal or alteration of dopaminergic therapy. Arch Infern Med 1991; 151:794-6.
2. Gibb WRG, Lees AJ. The Neuroleptic malignant syndrome - a review. Quarterly Journal of Medicine. New Series 1985; 56:421-9.
3. Simpson DM, Davis GC. Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine, Am J Psychiatry 1984; 141:797.
4. Lazarus A. Neuroleptic malignant syndrome and amantadine withdrawal Am J Psychiatry 1985; 142:142.
5. Figa-Talamanea L, Gualandi C, Di Meo L. Di Battista, Neri G, Lo RF. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors as a possible cause. Neurology 1985;35:258-61
6. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenic role for dopamine receptor blockade? Neurology 1981; 31:132-7.
7. Sechi GP, Tanda F, Mutani R. Fatal byperpyrexia after withdrawal of levodopa. Neurology 1984; 34:249-51.
8. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic mahgnantlike syndrome due to levodopa therapy withdrawal JAMA 1985;254:2792-5.
9. Gibb WRG, Griffith DNW Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome. Postgrad Med J 1986; 62:59-60.
10. Hirschorn KA, Greenberg HS. Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome. Clin Neuropharmacol 1988; 11:278-81.
11. Reutens DC, Hanison WB, Goldswaia PRT. Neuroleptic malignant syndrome complicanng levodopa withdrawal. Med J Aust 1991; 155:53-4.
12. Rainer C, Scheinost NA, Lefeber EJ Neuroleptic malignant syndrome - when levodopa withdrawal is the cause. Postgraduate Medicine 1991; 89; 175-80.
13. Kurlan R, Hamill R, Shoulson I. Neuroleptic malignant syndrome Neuropharmacol 1984; 7:109-20.
14. Pfeiffer RF, Sucha EL. On-off induced malignant hyperthermia Mov Disord 1989; 4:338-41
15. Shoop SA, Cernek PK. Carbidopa/levodopa in the treatment of neuroleptic malignant syndrome. Ann Pharmacother 1997; 31:119.
16. Nisijima K, Nogui M. Ishiguro T. The injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome. Biol Psychiatry 1997, 41:913-4.
17. Mezaki T, Ohtani SI, Abek, Hirono N, Udaka F. Kameyama M. Benign type of malignant syndrome. Lancet 1989; 1:49-50.